Brad Hively Sells 1,976,137 Shares of The Oncology Institute, Inc. (NASDAQ:TOI) Stock

The Oncology Institute, Inc. (NASDAQ:TOI - Get Free Report) Director Brad Hively sold 1,976,137 shares of the company's stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $2.87, for a total value of $5,671,513.19. Following the completion of the sale, the director now directly owns 603,501 shares in the company, valued at approximately $1,732,047.87. The trade was a 76.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Oncology Institute Stock Down 12.8%

Shares of Oncology Institute stock traded down $0.41 on Thursday, reaching $2.79. The company's stock had a trading volume of 3,632,360 shares, compared to its average volume of 986,196. The company has a quick ratio of 2.27, a current ratio of 2.49 and a debt-to-equity ratio of 5.91. The Oncology Institute, Inc. has a 52 week low of $0.13 and a 52 week high of $3.50. The company has a market capitalization of $248.96 million, a price-to-earnings ratio of -3.58 and a beta of 0.13. The firm's fifty day simple moving average is $2.49 and its two-hundred day simple moving average is $1.24.

Oncology Institute (NASDAQ:TOI - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.18) earnings per share for the quarter. The firm had revenue of $104.41 million for the quarter. Oncology Institute had a negative net margin of 17.63% and a negative return on equity of 186.83%.

Institutional Trading of Oncology Institute

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Tiff Advisory Services LLC lifted its stake in Oncology Institute by 13.2% in the 4th quarter. Tiff Advisory Services LLC now owns 2,979,141 shares of the company's stock worth $921,000 after purchasing an additional 346,256 shares in the last quarter. Josh Arnold Investment Consultant LLC purchased a new stake in Oncology Institute in the 1st quarter worth about $2,267,000. FreeGulliver LLC boosted its holdings in Oncology Institute by 219.3% during the 4th quarter. FreeGulliver LLC now owns 600,747 shares of the company's stock valued at $186,000 after acquiring an additional 412,578 shares during the period. Renaissance Technologies LLC lifted its holdings in Oncology Institute by 7.1% during the 4th quarter. Renaissance Technologies LLC now owns 182,000 shares of the company's stock valued at $56,000 after buying an additional 12,000 shares in the last quarter. Finally, Virtu Financial LLC purchased a new stake in shares of Oncology Institute in the 4th quarter worth $41,000. Hedge funds and other institutional investors own 36.86% of the company's stock.

Analyst Upgrades and Downgrades

Separately, BTIG Research began coverage on shares of Oncology Institute in a research note on Thursday, May 15th. They set a "buy" rating and a $7.00 target price for the company.

About Oncology Institute

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.